Literature DB >> 23106049

Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease.

Erik S Musiek1, Babak Saboury, Shipra Mishra, Yufen Chen, Janet S Reddin, Andrew B Newberg, Jayaram K Udupa, John A Detre, Frank Hofheinz, Drew Torigian, Abass Alavi.   

Abstract

The development of clinically-applicable quantitative methods for the analysis of brain fluorine-18 fluoro desoxyglucose-positron emission tomography ((18)F-FDG-PET) images is a major area of research in many neurologic diseases, particularly Alzheimer's disease (AD). Region of interest visualization, evaluation, and image registration (ROVER) is a novel commercially-available software package which provides automated partial volume corrected measures of volume and glucose uptake from (18)F-FDG PET data. We performed a pilot study of ROVER analysis of brain (18)F-FDG PET images for the first time in a small cohort of patients with AD and controls. Brain (18)F-FDG-PET and volumetric magnetic resonance imaging (MRI) were performed on 14 AD patients and 18 age-matched controls. Images were subjected to ROVER analysis, and voxel-based analysis using SPM5. Volumes by ROVER were 35% lower than MRI volumes in AD patients (as hypometabolic regions were excluded in ROVER-derived volume measurement ) while average ROVER- and MRI-derived cortical volumes were nearly identical in control population. Whole brain volumes when ROVER-derived and whole brain metabolic volumetric products (MVP) were significantly lower in AD and accurately distinguished AD patients from controls (Area Under the Curve (AUC) of Receiver Operator Characteristic (ROC) curves 0.89 and 0.86, respectively). This diagnostic accuracy was similar to voxel-based analyses. Analysis by ROVER of (18)F-FDG-PET images provides a unique index of metabolically-active brain volume, and can accurately distinguish between AD patients and controls as a proof of concept. In conclusion, our findings suggest that ROVER may serve as a useful quantitative adjunct to visual or regional assessment and aid analysis of whole-brain metabolism in AD and other neurologic and psychiatric diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23106049     DOI: 10.1967/s002449910052

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  9 in total

1.  SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.

Authors:  Thomas C Kwee; Gang Cheng; Marnix G E H Lam; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10       Impact factor: 9.236

2.  Global and regional brain glucose metabolism decline after systemic chemotherapy.

Authors:  Saeid Gholami; Eivind Antonsen Segtnan; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-07       Impact factor: 9.236

3.  Short-Term Practice Effects and Brain Hypometabolism: Preliminary Data from an FDG PET Study.

Authors:  Kevin Duff; Kevin P Horn; Norman L Foster; John M Hoffman
Journal:  Arch Clin Neuropsychol       Date:  2015-05       Impact factor: 2.813

4.  Diagnostic manifestations of total hemispheric glucose metabolism ratio in neuronal network diaschisis: diagnostic implications in Alzheimer's disease and mild cognitive impairment.

Authors:  Eivind A Segtnan; Alireza Majdi; Caius Constantinescu; Peter Grupe; Oke Gerke; Heini Í Dali; Olaf Emil Strøm; Jorun Holm; Abass Alavi; Saeed Sadigh-Eteghad; Lene Wermuth; Malene G Hildebrandt; Albert Gjedde; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-12       Impact factor: 9.236

5.  Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease.

Authors:  Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Thomas J Werner; Hongming Zhuang; Terence Gade; Abass Alavi; Stephen J Hunt
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

6.  FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity.

Authors:  Babak Saboury; Ali Salavati; Alex Brothers; Sandip Basu; Thomas C Kwee; Marnix G E H Lam; Roland Hustinx; Edouard Louis; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-20       Impact factor: 9.236

7.  Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study.

Authors:  Sarah Abdulla; Ali Salavati; Babak Saboury; Sandip Basu; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

8.  The occurrence of cerebrovascular atherosclerosis in Alzheimer's disease patients.

Authors:  Jing Yuan; Ge Wen; Yingjia Li; Changxing Liu
Journal:  Clin Interv Aging       Date:  2013-05-24       Impact factor: 4.458

Review 9.  Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.

Authors:  Chetsadaporn Promteangtrong; Marcus Kolber; Priya Ramchandra; Mateen Moghbel; Sina Houshmand; Michael Schöll; Thomas J Werner; Abass Alavi; Carlos Buchpiguel
Journal:  Dement Neuropsychol       Date:  2015 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.